Please login to the form below

Not currently logged in
Email:
Password:

Namenda

This page shows the latest Namenda news and features for those working in and with pharma, biotech and healthcare.

Forest said to be interested in $3bn Aptalis acquisition

Forest said to be interested in $3bn Aptalis acquisition

US for former blockbuster antidepressant Lexapro (escitalopram), as well as generic competition from 2015 for Alzheimer's disease therapy Namenda (memantine). ... With Lexapro and Namenda accounting for more than three quarters of company turnover at

Latest news

  • Lundbeck and Otsuka take Alzheimer's drug into phase III Lundbeck and Otsuka take Alzheimer's drug into phase III

    Regardless, it has been 10 years since the last new Alzheimer's treatment reached the market - Lundbeck's glutamate (NMDA) antagonist Ebixa (memantine), which is sold as Namenda by Forest Labs

  • Forest's net income down for Q3

    He said: "We have been working diligently for the past seven years to build a solid product development pipeline that will more than replace the loss of Lexapro and Namenda following

  • Forest Laboratories earnings rise

    Lexapro (escitalopram) and its Alzheimer's drug Namenda (memantine) lose their patent protection in the coming years. . ... expiration for both Lexapro in 2012 and Namenda in 2015 and provide growth," he said.

  • Lifting the fog

    Additionally, a patch formulation of donepezil is in development. Also approved for the treatment of moderate-to-severe AD is memantine (Namenda, Forest Laboratories), which was the first NMDA receptor antagonist

  • Forest Labs earnings fall in Q2

    revenues lost due to patent expiration for Lexapro in 2012 and [the Alzheimer's drug] Namenda (memantine) in 2015.".

More from news
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics